Wayfinder Biosciences

Wayfinder Biosciences is a drug discovery company developing a new class of orally available small molecules that target RNA structures to stop harmful proteins before they are made. Founded by RNA scientists from the University of Washington, Wayfinder's proprietary platform combines RNA-based sensors, experimental screening, and AI/ML to discover potent and selective RNA-targeting small molecules. The platform enables quantitative insights on small molecule binding, selectivity, and function at RNA targets — including the undruggable transcription factor c-MYC for oncology and additional targets in neurodegeneration. The company's technology is applicable across oncology, neurodegeneration, immunology, and rare disease, and Wayfinder has an active collaboration with Deerfield Science.